Literature DB >> 11442189

Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier.

M Furuichi1, T Chiba, K Abe, S Kogure, H Iijima, S Tsukahara, K Kashiwagi.   

Abstract

PURPOSE: To study prospectively using optical coherence tomography (OCT) whether topical latanoprost induces retinal disorders, such as cystoid macular edema, in patients with glaucoma and a normally functioning blood-ocular barrier.
METHODS: Sixty-eight eyes of 38 patients with glaucoma and no history of intraocular surgery, uveitis, or laser trabeculoplasty were studied. Before initiation of latanoprost treatment and after 1, 3, and 6 months of treatment, OCT images were taken, and the following tests were performed: visual acuity examination, fundus ophthalmoscopy, intraocular pressure measurement, and fundus color photography. To evaluate retinal thickness in the fovea accurately. OCT scanning was repeated six times, and the smallest value was used as the retinal thickness in the fovea.
RESULTS: Latanoprost ophthalmic solution did not influence retinal thickness in the fovea at any investigated time points compared with the time before instillation, and no changes were observed in visual acuity, ophthalmoscopic findings, and fundus photographs. The intraocular pressure was reduced significantly at all investigated time points compared with the time before instillation.
CONCLUSIONS: It is unlikely that topical latanoprost induces retinal disorders, such as cystoid macular edema, in glaucomatous eyes with a normally functioning blood-ocular barrier.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442189     DOI: 10.1097/00061198-200106000-00016

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  12 in total

1.  Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.

Authors:  Makoto Aihara; Fenghe Lu; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata
Journal:  Jpn J Ophthalmol       Date:  2021-09-08       Impact factor: 2.447

2.  Cystoid macular oedema within 24 h after a single application of latanoprost.

Authors:  Vlassis G Grigoropoulos; Ioannis Emfietzoglou; Pantelis Nikolaidis; Panagiotis G Theodossiadis; George P Theodossiadis
Journal:  Int Ophthalmol       Date:  2008-04-03       Impact factor: 2.031

3.  Travoprost in the management of open-angle glaucoma and ocular hypertension.

Authors:  Philippe Denis; David Covert; Anthony Realini
Journal:  Clin Ophthalmol       Date:  2007-03

4.  Prostaglandin-induced cystoid macular edema following routine cataract extraction.

Authors:  Negin Agange; Sameh Mosaed
Journal:  J Ophthalmol       Date:  2010-11-07       Impact factor: 1.909

5.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

Review 6.  Drug-induced macular edema.

Authors:  Olga E Makri; Ilias Georgalas; Constantine D Georgakopoulos
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

7.  Subtenon triamcinolone injection for postoperative cystoid macular edema associated with tafluprost.

Authors:  Kazuki Matsuura; Ryu Uotani; Yuki Terasaka
Journal:  Clin Ophthalmol       Date:  2013-07-24

8.  Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery.

Authors:  Sasan Moghimi; Mehdi Zandian; Golshan Latifi; Heydar Amini; Yadollah Eslami; Reza Zarei; Ghasem Fakhraie; Kouros Nouri-Mahdavi
Journal:  J Ophthalmic Vis Res       Date:  2012-10

9.  Successful treatment of prostaglandin-induced cystoid macular edema with subtenon triamcinolone.

Authors:  Kazuki Matsuura; Shinichi Sasaki; Ryu Uotani
Journal:  Clin Ophthalmol       Date:  2012-12-18

10.  Acute macular edema following intracorporeal prostaglandin injection for erectile dysfunction.

Authors:  Masumi G Asahi; Calvin Chou; Ron P Gallemore
Journal:  Int Med Case Rep J       Date:  2015-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.